FGI
CRL icon

Foresight Global Investors’s Charles River Laboratories CRL Stock Holding History

Foresight Global Investors’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-5,885
Closed -$1.19M – 42
2023
Q1 		$1.19M Buy
+5,885
New +$1.33M 0.85% 28

Other funds holding CRL

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Kayne Anderson Rudnick Investment Management
Kayne Anderson Rudnick Investment Management Los Angeles, California $34B AUM 6.31% 1-Year Est. Return
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $59.7B AUM 29.08% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $8.93B AUM 29.58% 1-Year Est. Return
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return

Foresight Global Investors's CRL Position: Q2 2023 in Review

Foresight Global Investors sold out of Charles River Laboratories (CRL) in Q2 2023, closing a stake of 5,885 shares — an estimated $1.19M sold.

Foresight Global Investors first reported a position in CRL in Q1 2023 and held it in 1 quarter. The position peaked at $1.19M in Q1 2023. 612 funds tracked by Wall St. Rank hold CRL as of Q2 2023.

  • Foresight Global Investors reported no remaining Charles River Laboratories position as of Q2 2023 after selling out during the quarter.
  • Foresight Global Investors sold 5,885 Charles River Laboratories shares in Q2 2023, an estimated $1.19M.
  • Foresight Global Investors first reported a position in Charles River Laboratories in Q1 2023 and held it in 1 quarter.
  • Foresight Global Investors's Charles River Laboratories position peaked at $1.19M in Q1 2023.
  • 612 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2023.

Based on Foresight Global Investors's 13F filing for Q2 2023, filed 24 Jul 2023.